Medication

Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR)…

Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…

An FDA advisory panel recommended that six investigational peptides be eligible for compounding, but the agency has not…

Aysen Slack, 65 and from Eastbourne, chose to pay privately for the pills once she heard about them.…

Dr Adam Staten, 43, a medical director at the private diagnostics clinic hub One Day Tests, said he…

Weight loss drugs may slow aging process Dr. Suneil Koliwad, Chief of the Division of Endocrinology and Metabolism…

While tried-and-true high cholesterol treatments like statins are an important way to protect your heart if you have…

A Colorado board voted Friday to allow the Attorney General’s Office to fight an injunction against a price…

The medicines regulator has issued a new safety warning for GLP-1-based drugs, like Ozempic, which could potentially cause…

New FDA-approved cholesterol pill lowers bad LDL | Tap to know more | Inshorts InshortsWe’re beating heart disease vox.comNewly approved…

The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the…

The applications could bring more affordable versions of one of the world’s most sought-after medicines into one…

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study